In this article, we will discuss Talazoparib (Dosage Overview). So, let’s get started.
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2
(HER2)-negative locally advanced or metastatic breast cancer.
The recommended dose of Talazoparib is 1 mg taken orally once daily, with or without food. The 0.25 mg capsule is available for dose reduction.
Patients should be treated until disease progression or unacceptable toxicity occurs.
The hard capsules should be swallowed whole and must not be opened or dissolved. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.